Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：33

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[31] Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study
Baumstarck, K.
Pelletier, J.
Boucekine, M.
Auquier, P.
[J]. REVUE NEUROLOGIQUE, 2015, 171 (02) : 173 - 180
[32] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
Alroughani, Raed
Huppke, Peter
Mazurkiewicz-Beldzinska, Maria
Blaschek, Astrid
Valis, Martin
Aaen, Gregory
Pultz, Joe
Peng, Xiaomei
Beynon, Vanessa
[J]. FRONTIERS IN NEUROLOGY, 2021, 11
[33] Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study
Peter Joseph Jongen
Dirk Lehnick
Jan Koeman
Stephan Frequin
Dorothea Heersema
Bert Kornips
Angelique Schyns-Soeterboek
Leo H. Visser
Paul Schiphof
Anton Valkenburg
Johan Hiel
[J]. Journal of Neurology, 2014, 261 : 1469 - 1476
[34] Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study
Jongen, Peter Joseph
Lehnick, Dirk
Koeman, Jan
Frequin, Stephan
Heersema, Dorothea
Kornips, Bert
Schyns-Soeterboek, Angelique
Visser, Leo H.
Schiphof, Paul
Valkenburg, Anton
Hiel, Johan
[J]. JOURNAL OF NEUROLOGY, 2014, 261 (08) : 1469 - 1476
[35] Establishing an Evaluation Scale for the Perception of Quality of Life Related to Relapsing-Remitting Forms of Multiple Sclerosis and Feasibility Study
Baroin, A.
Mokadym, H.
Chopard, G.
Lavier, A.
Berger, E.
Rumbach, L.
Rude, N.
[J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2012, 122 (01) : 9 - 16
[36] Impact of electroacupuncture on quality of life for patients with Relapsing-Remitting Multiple Sclerosis under treatment with immunomodulators: A randomized study
Quispe-Cabanillas, Juan G.
Damasceno, Alfredo
von Glehn, Felipe
Brandao, Carlos O.
Damasceno, Benito P.
Silveira, Wanderley D.
Santos, Leonilda M. B.
[J]. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12
[37] Health-related quality of life in patients with multiple sclerosis
Vazquez Gomez, Lazaro Aurelio
Hidalgo Mesa, Carlos
Beltran Gonzalez, Benita Mabel
Broche Perez, Yunier
Mederos Herrera, Ana Maria
[J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (01): : 44 - 51
[38] High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open label Danish study
Schreiber, Karen
Kant, Matthias
Pfleger, Claudia
Jensen, Henrik Boye
Oesterbergs, Ole
Hald, Anne Rieper
Nielsen, Frederik K.
Rubak, Sune
[J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1139 - 1150
[39] Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE
Gold, Ralf
Arnold, Douglas L.
Bar-Or, Amit
Fox, Robert J.
Kappos, Ludwig
Chen, Chongshu
Parks, Becky
Miller, Catherine
[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
[40] Motor symptoms and the quality of life of relapsing-remitting multiple sclerosis patients in a specialized center in South of Brazil
Jorge, Francielle Fontana
Finkelsztejn, Alessandro
Rodrigues, Luciano Palmeiro
[J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (10) : 895 - 899

← 1 2 3 4 5 →